1Clinical Pipeline

2Emerging pipeline

Transforming Drug Discovery for the Next Wave of Medicines

BXCL701 Revolutionizing drug development and translation research in Immuno-Oncology (IO)

BXCL501 Treating the Symptoms of Neuropsychiatric and Neurodegenerative Diseases

BXCL702 Developing the drug as mono-therapy and in combination with immune-checkpoint inhibitors

Learn more

The Healing Power of Science

Medicines that change lives



Targeting immuno-oncology and neuroscience disorders with significant unmet medical need



Proprietary drug re-innovation approach to other underserved areas in oncology and neuroscience


Higher Probability

Generating first in class drug candidates with a higher probability of clinical and regulatory success


Therapeutic Benefit

Potential to provide significant therapeutic benefit to the patients who need close medical attention

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company that utilizes novel artificial intelligence, or AI, to identify the next wave of medicines across neuroscience and immuno-oncology.
Our drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. We believe that this differentiated approach has the potential to reduce the cost and time of drug development in diseases with substantial unmet medical need.


Press Coverage

21 April 2017

BXCL701, Immune Checkpoint Inhibitors Combo Holds Promise for Castration-resistant Prostate Cancer Patients

View all Press Coverages

News Releases

13 February 2018

BioXcel Therapeutics Files Registration Statement for Proposed Initial Public Offering

View all News Releases